CompanySLN SLNCFNasdaq, OTCLondon

Silence Therapeutics plc

Silence Therapeutics develops siRNA therapies using its mRNAi GOLD platform to target genes causing disease.

SEC EDGAR ClinicalTrials.gov silence-therapeutics.com

424B4Sep 28Latest SEC filing

Aug 12Latest story

August 2026

Silence Therapeutics prices $175 million ADS offering at $13.50 per share

Aug 12FinancingSilence Therapeutics plc

Silence Therapeutics reports positive Phase 2 topline data for divesiran in polycythemia vera

Aug 10Clinical readoutSilence Therapeutics plc

Silence Therapeutics reports Q2 2026 results and divesiran trial progress

Aug 10Quarterly updateSilence Therapeutics plc

July 2026

Silence Therapeutics discloses separation terms for Craig Tooman in amended 8-K

Jul 16PeopleSilence Therapeutics plc